M&A Deal Summary

Amygdala Neurosciences Acquires Gilead Sciences - GS-6637

On February 16, 2017, Amygdala Neurosciences acquired life science company Gilead Sciences - GS-6637 from Gilead Sciences

Acquisition Highlights
  • This is Amygdala Neurosciences’ 1st transaction in the Life Science sector.
  • This is Amygdala Neurosciences’ 1st transaction in the United States.
  • This is Amygdala Neurosciences’ 1st transaction in California.

M&A Deal Summary
Date 2017-02-16
Target Gilead Sciences - GS-6637
Sector Life Science
Buyer(s) Amygdala Neurosciences
Sellers(s) Gilead Sciences
Deal Type Divestiture

Target

Gilead Sciences - GS-6637

Foster City, California, United States
Gilead Sciences, Inc. - GS-6637 is a Phase-2 ready compound that utilizes a novel pathway for the treatment of addiction. GS-6637 is highly selective ALDH2 inhibitor that modifies dopaminergic tone by preventing pathophysiologic dopamine surges and associated craving without changes to basal dopamine.

Search 202,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Amygdala Neurosciences

Palo Alto, California, United States
Category Company
Sector Life Science
DESCRIPTION

Amygdala Neurosciences, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class drug candidates for the treatment of addiction disorders.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2017) 1 of 1

Seller(S) 1

SELLER

Gilead Sciences

Foster City, California, United States
Category Company
Founded 1987
Sector Life Science
Employees18,000
Revenue 27.1B USD (2023)
DESCRIPTION
Entrance to Gilead Sciences' corporate headquarters in Foster City, California.
Entrance to Gilead Sciences' corporate headquarters in Foster City, California.

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. Gilead Sciences was founded in 1987 and is Based in Foster City, California.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 3 of 3
Type (Divestiture) 3 of 3
State (California) 3 of 3
Country (United States) 3 of 3
Year (2017) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-04-04 Nimbus Apollo

United States

Nimbus Apollo program includes the lead candidate NDI-010976, an ACC inhibitor, and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis (NASH), and for the potential treatment of hepatocellular carcinoma (HCC) and other diseases.

Buy $400M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-08-28 Kite Pharma

Santa Monica, California, United States

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system's ability to recognize and eradicate tumors. Kite Pharma was formed in 2009 and is based in Santa Monica, California.

Buy $11.9B
Mergr

Product

Company

Legal